Melanoma News and Research

Latest Melanoma News and Research

Loyola's pediatric dermatologists highlight risks related to indoor tanning

Prom season is right around the corner and with that comes dress shopping and trips to the local tanning salons for many girls.

21 May 2014

Mayo Clinic study provides key insights into aggressive form of pancreatic cancer

Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.

21 May 2014

Research provides key insights into most aggressive form of pancreatic cancer

Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.

21 May 2014

Substance from pine bark is a potential source for treating melanoma

A substance that comes from pine bark is a potential source for a new treatment of melanoma, according to Penn State College of Medicine researchers.

21 May 2014

Scientists uncover early steps of totipotency in sperm precursors

In the body, a skin cell will always be skin, and a heart cell will always be heart. But in the first hours of life, cells in the nascent embryo become totipotent: they have the incredible flexibility to mature into skin, heart, gut, or any type of cell.

20 May 2014

Cancer Council urges Queenslanders to get to know their own skin

Cancer Council is urging Queenslanders to get to know their own skin and stay vigilant about early detection, with reports of misdiagnosis for some types of melanoma in the Australasian Journal of Dermatology.

19 May 2014

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system.

19 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study released ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Ill.

15 May 2014

Sports Authority, MRA partner to educate public about melanoma

Sports Authority, one of the nation's largest full-line sporting goods retailers, today announced that they have partnered with the Melanoma Research Alliance, the largest private funder of melanoma research, to inform the public about this deadly form of skin cancer and to raise funds to support studies aimed at its treatment and cure. This is the fourth consecutive year Sports Authority has participated in and supported the effort.

12 May 2014

Experimental antibody temporarily halts progression of neuroblastoma in children

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.

9 May 2014

Regular doctor visits may reduce melanoma mortality, says study

The risk of dying from the most dangerous type of skin cancer is significantly reduced with regular doctor visits, according to a Henry Ford Hospital study.

8 May 2014

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

The Translational Genomics Research Institute (TGen) and George Mason University today announced the creation of a strategic research alliance to benefit patients with cancer and other life-threatening illnesses.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

The Jeffrey Epstein VI Foundation supports Sunscreen Innovation Act to combat melanoma

Sunscreens are long overdue for a makeover: in fact active ingredients in US sunscreens haven't been updated for fifteen years, despite dermatologist and oncologist warnings that US sunscreens are not effective enough.

6 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Melanoma News and Research

Latest Melanoma News and Research

Loyola's pediatric dermatologists highlight risks related to indoor tanning

Mayo Clinic study provides key insights into aggressive form of pancreatic cancer

Research provides key insights into most aggressive form of pancreatic cancer

Substance from pine bark is a potential source for treating melanoma

Scientists uncover early steps of totipotency in sperm precursors

Cancer Council urges Queenslanders to get to know their own skin

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Sports Authority, MRA partner to educate public about melanoma

Experimental antibody temporarily halts progression of neuroblastoma in children

Regular doctor visits may reduce melanoma mortality, says study

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

FDA accepts Merck's MK-3475 BLA for review

The Jeffrey Epstein VI Foundation supports Sunscreen Innovation Act to combat melanoma

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in